albumin-hitchhiking nanobody-STING agonist

An albumin-hitchhiking nanobody-STING agonist conjugate is a modular cancer immunotherapy platform developed by researchers at Vanderbilt University. The platform consists of a llama-derived single-domain antibody (nanobody) that binds to endogenous serum albumin, covalently conjugated to a stimulator of interferon genes (STING) agonist payload. By hitchhiking on circulating albumin, the conjugate exhibits significantly extended circulation half-life and enhanced accumulation in the tumor microenvironment (TME). Once localized in the tumor, the STING agonist payload activates the STING pathway, promoting innate immune activation, increasing the infiltration of dendritic cells and inflammatory macrophages, and reversing TME-mediated immunosuppression. This approach has been shown to enhance the therapeutic efficacy of adoptive cell therapies (ACT) and immune checkpoint inhibitors in preclinical solid tumor models.

Other names

albumin-hitchhiking nanobody-STING agonist conjugatealbumin-hitchhiking nanobody-STING agonist conjugatesalbumin-hitchhiking nanobody–STING agonistnanobody-STING agonist